Abstract
Efficacy of a VIC-1911 combination with adavosertib in parental, AfaR, and ErlR HNSCC cell models. A, Loewe synergy plot showing synergistic interaction between VIC-1911 and adavosertib in parental, ErlR, and AfaR cell models treated for 72 hours, n = 3. B, Percentage of cells in G2–M (4N DNA content) for parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours. C and D, Quantification of dead FaDu (C) and Cal27 (D) parental, ErlR, and AfaR cell models treated with vehicle, adavosertib (0.5 μmol/L), VIC-1911 (0.25 μmol/L), or combination for 72 hours (n = 3). E and F, Representative Western blot images showing PARP and cleaved PARP (cPARP) for parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours, n = 3. G and H, Representative images (G) and quantitation of viability based on CellTiter-Glo (H) for spheroids of indicated cell models. I and J, Representative images (I) and quantification (J) of clonogenic assays for cells treated with the drug concentration indicated in I for 11 days. Bar graphs display data normalized to DMSO values of each cell line. P values are based on one-way ANOVA followed by the Tukey multiple comparison test. ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.